Thomas R. Ulich
Keine laufenden Positionen mehr
Karriereverlauf von Thomas R. Ulich
Ehemalige bekannte Positionen von Thomas R. Ulich
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Technik-/Wissenschafts-/F&E-Leiter | 24.02.2014 | 30.08.2017 |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | 01.01.2010 |
| ALNYLAM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | 01.01.2004 |
Amgen Canada, Inc.
 Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1993 | 01.01.2001 |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 13.01.2010 | - |
| Wayne State University (Michigan) | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
Ausbildung von Thomas R. Ulich
| Dartmouth College | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Kanada | 4 |
Operativ
| Chief Tech/Sci/R&D Officer | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Health Technology |
- Börse
- Insiders
- Thomas R. Ulich
- Erfahrung